
    
      To determine the feasibility and toxicity of neoadjuvant hypofractioned radiotherapy
      concurrently with weekly gemcitabine and an EGFR tyrosine-kinase inhibitor (OSI-774, Tarceva)
      in the treatment of patients with resectable pancreatic cancer.
    
  